Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease-Reference-Cited by-同舟云学术

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease

Published:2018-11-20 Issue:19 Volume:320 Page:2010
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Meijer Esther¹,Visser Folkert W.¹²,van Aerts Rene M. M.³,Blijdorp Charles J.⁴,Casteleijn Niek F.¹,D‘Agnolo Hedwig M. A.³,Dekker Shosha E. I.⁵,Drenth Joost P. H.³,de Fijter Johan W.⁵,van Gastel Maatje D. A.¹,Gevers Tom J.³,Lantinga Marten A.³,Losekoot Monique⁶,Messchendorp A. Lianne¹,Neijenhuis Myrte K.³,Pena Michelle J.⁷,Peters Dorien J. M.⁶,Salih Mahdi⁴,Soonawala Darius⁵⁸,Spithoven Edwin M.¹,Wetzels Jack F.⁹,Zietse Robert⁴,Gansevoort Ron T.¹,

Affiliation:

1. Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands

2. Department of Internal Medicine, Hospital Group Twente, Almelo, the Netherlands

3. Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands

4. Department of Internal Medicine, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands

5. Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands

6. Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands

7. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University, Hospital Groningen, Groningen, the Netherlands

8. Department of Internal Medicine, Haga Teaching Hospital, The Hague, the Netherlands.

9. Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference40 articles.

1. Autosomal dominant polycystic kidney disease: the changing face of clinical management.;Ong;Lancet,2015

2. Prevalence of autosomal dominant polycystic kidney disease in the European Union.;Willey;Nephrol Dial Transplant,2017

3. Renal replacement therapy for ADPKD in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry.;Spithoven;Nephrol Dial Transplant,2014

4. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease.;Smith;J Am Soc Nephrol,2006

5. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.;Torres;J Am Soc Nephrol,2014

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan;Nephrology;2024-03-10

2. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD;Clinical Journal of the American Society of Nephrology;2024-02-26

3. Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease;Journal of the American Society of Nephrology;2023-12-11

4. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide;European Journal of Clinical Investigation;2023-12-09

5. Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management;Seminars in Nephrology;2023-11